HWGB 9601 Share Price
RM0.47
52 Weeks Range : 0.12 - 1.52
3.0/10
(Expert Score)
Product is rated as #223 in category BM Industrial Products & Services
PROS:
- Positive Cash Company
- Very High Trading Value
CONS:
- Making Huge Loss
- No Dividend Declared
- Very Low Price-to-Tangible
- Very High Gearing
klse: Ho Wah Genting Bhd
Corporate Information
Board : Main
Shariah : Shariah Compliant
Sector : Electrical Products Copper
Address: Wisma Ho Wah Genting,1st Floor, No. 35
, Jalan Maharajalela, 50150, Kuala Lumpur
Contact: +603-21438811
Website: https://www.hwgenting.com.my/
Corporate Background
Ho Wah Genting Berhad is an investment holding company. The Company, through its subsidiaries, manufactures wires, cables, molded power supply cord sets, and cable assemblies for electrical and electronic devices and equipment.
Genaral Info: HWGB 9601
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 24/02/21 | 90,527 | -21,227 | -20,924 |
| 26/11/20 | 96,092 | 2 | -773 |
| 27/08/20 | 53,267 | -1,699 | -1,869 |
| 28/05/20 | 48,175 | 1,954 | 1,169 |
| 27/02/20 | 34,378 | -5,572 | -5,084 |
| 26/11/19 | 47,222 | -379 | -722 |
| 21/08/19 | 62,027 | 884 | -174 |
| 30/05/19 | 37,343 | -756 | -1,010 |
| 28/02/19 | 38,448 | 1,550 | -28,726 |
| 22/11/18 | 44,102 | 121 | -2,106 |
| 28/08/18 | 37,454 | 614 | 562 |
| 30/05/18 | 39,703 | -2,923 | -2,783 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 288,061 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | -22,428 |
| Last 4 Quarter EPS (sen) | -4.51 |
| Last 4 Quarter PER | – |
| Last 4 Quarter Dividend (sen) | – |
| Last 4 Quarter Dividend Yield (%) | – |
| Net Tangible Assets (RM) | 0.07 |
| Goodwill (RM) | 0 |
| Cash (RM’000) | 20,540 |
| Debt (RM’000) | 21,690 |
| Total Debt (RM’000) | 91,530 |
| Net Assets (RM’000) | 40,500 |
| Current Ratio | 1.24 |
| Quick Ratio | 0.60 |
| Cash Ratio | 0.17 |
Technical
Technical Analysis
| MACD (26 vs 12) | -0.025 |
|---|---|
| Exponential Moving Average 5 | 0.479 |
| Exponential Moving Average 20 | 0.512 |
| Exponential Moving Average 90 | 0.593 |
| Relative Strength Index 14 | 0.15 |
| Stochastic %D 3 | 0.12 |
| Stochastic %K 14 | 0.09 |
13 reviews for HWGB 9601
Show all
Most Helpful
Highest Rating
Lowest Rating
The Edge –
Ho Wah Genting Berhad, through its wholly-owned subsidiary HWGB Biotech Sdn Bhd has been successfully granted the Pharmacist’s Poisons Licence (Type A License) from the Pharmaceutical Services Division of Ministry of Health Malaysia which enable the Company to import, store and deal generally by wholesale all controlled medicine.
The Star –
Ho Wah Genting Bhd has obtained a full pharmaceutical product registration approval for its wholly-owned subsidiary, Astramern Sdn Bhd’s health supplement, Astramern Astra H, from the National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health. The NPRA’s full approval for the health supplement and traditional medicine is granted for the maximum period of five years and renewable thereof, it said in a statement here today.
The Edge –
Ho Wah Genting Bhd is planning to raise up to RM34.58 million via a private placement. The group said it would be placing up to 60.67 million new shares, representing 10% of its share capital of 606.68 million shares, among third-party investors. Ho Wah Genting plans to use up to RM12 million of the placement proceeds to purchase healthcare products and for research and development activities for its healthcare-related business. Another RM10 million would be used to fully repay a loan from Hong Kong-based Prime King Investment Ltd. Up to RM11.77 million of the proceeds would be used for general working capital requirements.
The Edge –
Ho Wah Genting Bhd’s share price declined 22% to 69 sen from 89 sen between Dec 7 and 14. Chinese national Zhang Yong, through ZY Sales & Distribution Sdn Bhd, ceased to be a substantial shareholder of HWG after disposing of his entire stake on the open market. It was only in October that Zhang emerged as a shareholder of HWG through ZY Sales & Distribution after acquiring 90 million shares or a 17.09% stake. HWG, which started the year as a penny stock trading at 11 sen, hit a high of RM1.29 on Aug 11 on speculative fervour surrounding the Covid-19 theme, but has been on a decline since.
The Edge –
Ho Wah Genting Bhd said its wholly-owned subsidiary has obtained a one-year conditional approval from Indonesia’s health ministry to manufacture medical products such as surgical face masks, Covid-19 rapid test cassettes and liquid chemical sterilants.
The Star –
US-based E-MO Biology Inc, the joint-venture partner of Ho Wah Genting Bhd’s wholly-owned subsidiary, HWGB Biotech Sdn Bhd, has obtained approval from the US Food and Drug Administration (FDA) to conduct phase IV clinical trials for a vaccine against Covid-19. In a statement, HWGB said HWGB Biotech would invest US$1mil (RM4.16mil) and would be entitled to 40% of the total net profit. With the FDA approval, HWGB chief executive officer Datuk Aaron Lim said the repurposing of the proven polio virus vaccines could fast track the Covid-19 vaccine development to save lives
The Edge –
A report that Malaysia will be a priority recipient of China’s COVID-19 vaccine bodes well for the pharmaceutical counters and companies which had secured the vaccine deals. Ho Wah Genting, of which its wholly-owned subsidiary, HWGB Biotech Sdn Bhd entered into a Memorandum of Understanding (MoU) with Xinkexian (Beijing) Biotechnology Co, Ltd (XKX) last month to consider appointing XKX as its non-exclusive manufacturer to produce COVID-19 vaccines, also improved 10 sen to 74 sen.
The Edge –
The company has been on investors’ radar screens since the coronavirus outbreak, initially over the distribution of Covid-19 test kits. However, it upped its game in August when it declared that it was officially in the race to produce a vaccine. However, there is scepticism over whether its ventures will succeed. Leinves PLT chief investment officer William Ng expresses doubts over HWGB’s plan to produce Covid-19 vaccines. He says HWGB does not have an established track record in the pharmaceutical industry
The Edge –
HWGB’s joint venture partner, US-based E-MO Biology Inc (EBI), has entered into three research and development (R&D) agreements to produce COVID-19 vaccines.
BURSA MALAYSIA –
The Group’s revenue for the current quarter increased by RM5.09 million or 10.6% compared to its immediate preceding quarter. The higher revenue in the current quarter was due to higher demand from existing customers.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 1.34 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 21.2 million and auditor’s remuneration of 125 thousands
BURSA MALAYSIA –
The Group’s revenue for the current quarter increased by RM13.79 million or 40.1% compared to its preceding quarter. The higher revenue was due to higher demand from existing customers. The Group recorded a PBT of RM1.95 million in the current quarter as compared to a LBT of RM5.60 million in the preceding quarter. The higher LBT was mainly due to an allowance of expected credit loss on amount due from an associate of RM4.00 million and lower profit generated from the Group’s lower revenue recorded.
Investing Malaysia –
Average investing volume for Ho Wah Genting Bhd in the past three months in stock market was 1171.2k lots
Investing Malaysia –
HWGB gets a score of 6.55 in our equity and assets quality test based on current share price of RM0.12
Investing Malaysia –
Ho Wah Genting Bhd gets a score of 8.31 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 9601 in Bursa Malaysia did not propose any dividend for the past few years
Investing Malaysia –
HWGB is forecasted to made loss of 2.31 millions, with an adjusted market capitalization of 56.09 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 1.57 million. It was fair compared to average in listed companies, considering the employees’ remuneration of 19.2 million and auditor’s remuneration of 126 thousands